- Home
- NLSP vs IMCC Comparison
NLSP vs IMCC Comparison
Compare NLSP & IMCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NLSP
- IMCC
- Stock Information
- Founded
- NLSP 2015
- IMCC 1980
- Country
- NLSP Switzerland
- IMCC Israel
- Employees
- NLSP N/A
- IMCC N/A
- Industry
- NLSP Biotechnology: Pharmaceutical Preparations
- IMCC Medicinal Chemicals and Botanical Products
- Sector
- NLSP Health Care
- IMCC Health Care
- Exchange
- NLSP Nasdaq
- IMCC Nasdaq
- Market Cap
- NLSP 12.4M
- IMCC 5.3M
- IPO Year
- NLSP 2021
- IMCC N/A
- Fundamental
- Price
- NLSP $2.86
- IMCC $2.48
- Analyst Decision
- NLSP
- IMCC
- Analyst Count
- NLSP 0
- IMCC 0
- Target Price
- NLSP N/A
- IMCC N/A
- AVG Volume (30 Days)
- NLSP 365.2K
- IMCC 406.8K
- Earning Date
- NLSP 07-07-2025
- IMCC 08-13-2025
- Dividend Yield
- NLSP N/A
- IMCC N/A
- EPS Growth
- NLSP N/A
- IMCC N/A
- EPS
- NLSP N/A
- IMCC N/A
- Revenue
- NLSP N/A
- IMCC $37,894,737.00
- Revenue This Year
- NLSP N/A
- IMCC $47.12
- Revenue Next Year
- NLSP N/A
- IMCC $12.83
- P/E Ratio
- NLSP N/A
- IMCC N/A
- Revenue Growth
- NLSP N/A
- IMCC 12.68
- 52 Week Low
- NLSP $1.30
- IMCC $1.29
- 52 Week High
- NLSP $15.59
- IMCC $7.12
- Technical
- Relative Strength Index (RSI)
- NLSP 67.56
- IMCC 47.67
- Support Level
- NLSP $2.19
- IMCC $2.67
- Resistance Level
- NLSP $2.54
- IMCC $3.35
- Average True Range (ATR)
- NLSP 0.19
- IMCC 0.40
- MACD
- NLSP 0.02
- IMCC -0.07
- Stochastic Oscillator
- NLSP 82.76
- IMCC 21.90
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.
About IMCC IM Cannabis Corp.
IM Cannabis Corp is a Canada-based international medical cannabis company. It operates in the field of medical cannabis, through Focus Medical Herbs Ltd. (Focus), which holds a cultivation license to breed, grow, and supply medical cannabis products The majority of its revenues are generated from sales of medical cannabis products to customers in Israel. The remaining revenues are generated from sales of medical cannabis, as well as other products, to customers in Germany. Geographically, the majority is from Israel.